These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9758326)

  • 1. Another report of adverse reactions to immediate-release nifedipine.
    Fami MJ; Ho NT; Mason CM
    Pharmacotherapy; 1998; 18(5):1133-5. PubMed ID: 9758326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety of short-acting nifedipine in children with hypertension.
    Egger DW; Deming DD; Hamada N; Perkin RM; Sahney S
    Pediatr Nephrol; 2002 Jan; 17(1):35-40. PubMed ID: 11793132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypotension and coronary events on nifedipine: reassessing nifedipine safety.
    Prescrire Int; 1998 Jun; 7(35):90-1. PubMed ID: 10342928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
    Nakayama J; Koga T; Furue M
    Eur J Dermatol; 1998 Dec; 8(8):563-8. PubMed ID: 9889429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers for tocolysis: a review of their role and safety following reports of serious adverse events.
    Oei SG
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):137-45. PubMed ID: 16567033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Immediate-Release Nifedipine.
    Means L; Benken ST; Tesoro EP
    J Cardiovasc Pharmacol; 2016 Nov; 68(5):395-399. PubMed ID: 27525576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effects of two modified release preparations of nifedipine-nifedipine retard 10 mg twice daily and nifedipine GITS 20 mg once daily--in the treatment of mild to moderate hypertension.
    Kirby BJ; Kitchin NR
    Int J Clin Pract; 1999; 53(5):339-43. PubMed ID: 10695096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; López JE; Rodríguez M; Chayán L; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2007; 24(3):471-93. PubMed ID: 17612946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of sublingual nifedipine: a continuing concern.
    Messerli FH; Grossman E
    Arch Intern Med; 1999 Oct; 159(19):2259-60. PubMed ID: 10547164
    [No Abstract]   [Full Text] [Related]  

  • 11. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension.
    Peters FP; de Zwaan C; Kho L
    Arch Intern Med; 1997 Dec 8-22; 157(22):2665-6. PubMed ID: 9531240
    [No Abstract]   [Full Text] [Related]  

  • 12. Nifedipine trials.
    Rafflenbeul W
    Circulation; 1996 Apr; 93(7):1473-4. PubMed ID: 8641042
    [No Abstract]   [Full Text] [Related]  

  • 13. Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing.
    Ricciardi MJ; Bossone E; Bach DS; Armstrong WF; Rubenfire M
    Chest; 1999 Nov; 116(5):1218-23. PubMed ID: 10559078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises.
    Truttmann AC; Zehnder-Schlapbach S; Bianchetti MG
    Pediatr Nephrol; 1998 Apr; 12(3):259. PubMed ID: 9630050
    [No Abstract]   [Full Text] [Related]  

  • 15. Depression--an adverse event with nifedipine.
    Patalia AH; Rathod NR; Gandhi RR; Gohel DR; Oza YK
    J Assoc Physicians India; 2002 Nov; 50():1432-4. PubMed ID: 12583478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment with nifedipine retard: increasing doses as a therapeutic method].
    Lobos Berajano JM; Lahoz Rallo F; Seguido Aliaga P; Castellanos Maroto J; Robles Pérez R
    Rev Clin Esp; 1989 Jan; 184(1):47-9. PubMed ID: 2704870
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse reactions to short-acting nifedipine in hypertensive crises.
    Spizzirri F; Rahman R
    Pediatr Nephrol; 1999 May; 13(4):366. PubMed ID: 10454793
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
    Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension.
    Wachter RM
    Arch Intern Med; 1987 Mar; 147(3):556-8. PubMed ID: 3827433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.